Melinta

MLNT NASDAQ
5.96
+0.07
+1.19%
After Hours: 5.85 -0.11 -1.85% 18:26 06/25 EDT
Open
5.95
Prev Close
5.89
High
6.59
Low
5.62
Volume
4.20M
Avg Vol (3M)
2.20M
52 Week High
35.50
52 Week Low
1.620
% Turnover
35.69%
Market Cap
70.21M
1D
5D
1M
3M
1Y
5Y

Related

Webull offers Melinta MLNT stock price, real time market quotes, professional analyst ratings, and in-depth charts, You can share investing ideas in community to communicate with others and learn trading skills.

Company Profile

Melinta Therapeutics, Inc. develops and commercializes novel antibiotics designed to provide therapeutic solutions. The Company’s lead product is Baxdela, an antibiotic approved by the United States food and drug administration (FDA) for use in the treatment of acute bacterial skin and skin structure infections (ABSSSI). The Company also has an extensive pipeline of preclinical and clinical stage products This pipeline includes many important classes of antibiotics, each targeted at a different segment of the anti-infective market.
MORE >

Recently

Name
Price
%Change